ProfileJobs

C. R. Bard

Suggest Edit
Technologymedical devicesmedtechsurgical solutions
C. R. Bard (now branded as Bard) is a developer, manufacturer, and marketer of medical technologies in the fields of vascular, urology, oncology, and surgical specialties. The company markets its products and services worldwide to hospitals, individual healthcare professionals, extended care facilities, and alternate site facilities. 
Revenue(FY, 2016)
$3.7 B

Employee Rating

4.1
TypeSubsidiary
Parent CompanyBecton Dickinson
HQFranklin Lakes, NJ, US
Founded1907
Websitecrbard.com
Cybersecurity ratingBMore
C. R. Bard was founded in 1907 and is headquartered in Franklin Lakes, NJ, US
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

C. R. Bard Office Locations

C. R. Bard has offices in Franklin Lakes, Chelmsford, Covington, Salt Lake City and in 31 other locations
Artarmon, AU
22 Lambs Rd
Wien, AT
Rinnböckstraße 3
Olen, BE
Hagelberg 2
São Paulo, BR
Rua Alexandre Dumas, 2 - 100 - 10° andar - Santo Amaro
Oakville, CA
2715 Bristol Cir #1
Las Condes, CL
Av. Pdte. Riesco 5335, piso 9
Show all (42)

C. R. Bard Financials and Metrics

Summary Metrics

Founding Date

1907
C. R. Bard is a subsidiary of Becton Dickinson

C. R. Bard Revenue

Embed Graph
View revenue for all periods
C. R. Bard's revenue was reported to be $3.71 b in FY, 2016 which is a 8.7% increase from the previous period.
Annual
USDFY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016

Revenue

2.7b2.9b3.0b3.0b3.3b3.4b3.7b

Revenue growth, %

9%3%9%

Cost of goods sold

1.0b1.1b1.1b1.2b1.3b1.3b1.4b

Gross profit

1.7b1.8b1.8b1.9b2.1b2.1b2.3b
Quarterly
USDQ1, 2010Q2, 2010Q1, 2011Q2, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Revenue

650.8m673.9m700.3m725.0m730.0m742.6m722.9m740.3m759.9m758.0m799.3m827.1m830.0m819.7m859.8m865.7m873.5m931.5m941.9m938.8m979.7m989.8m

Cost of goods sold

252.7m251.7m264.8m275.5m279.4m285.7m272.6m295.3m296.6m291.9m309.5m320.7m308.9m311.2m333.7m336.3m320.4m351.0m352.2m354.2m361.3m379.2m

Gross profit

398.1m422.2m435.5m449.5m450.6m456.9m450.3m445.0m463.3m466.1m489.8m506.4m521.1m508.5m526.1m529.4m553.1m580.5m589.7m584.6m618.4m610.6m

Gross profit Margin, %

61%63%62%62%62%62%62%60%61%61%61%61%63%62%61%61%63%62%63%62%63%62%
show all
Annual
USDFY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016

Cash

641.4m596.4m896.3m1.1b960.1m950.5m905.0m

Accounts Receivable

460.8m488.9m480.9m479.6m455.2m445.1m

Prepaid Expenses

75.5m73.1m73.9m93.2m114.8m79.6m

Inventories

308.9m319.2m328.5m356.2m376.2m413.7m483.0m
Quarterly
USDQ1, 2010Q2, 2010Q3, 2010Q1, 2011Q2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Cash

720.4m592.9m662.2m748.3m911.9m767.0m674.6m714.0m809.1m879.3m859.4m781.7m939.9m996.1m971.7m1.0b1.1b1.0b765.0m797.8m996.4m890.7m976.5m1.2b

Accounts Receivable

430.8m420.8m435.0m459.7m474.2m476.5m505.3m505.9m475.0m448.6m467.6m456.5m452.6m454.0m443.3m436.5m453.7m441.9m458.1m467.2m455.8m450.0m476.7m503.0m

Prepaid Expenses

33.3m43.0m54.6m71.7m119.6m84.6m58.0m79.0m79.7m69.0m98.3m103.8m97.9m122.3m105.3m125.9m93.3m80.1m104.2m115.4m92.9m283.8m270.4m253.3m

Inventories

279.1m281.8m315.3m327.6m331.6m329.8m323.9m330.5m335.9m332.6m324.6m332.1m364.2m374.3m379.9m377.8m383.6m381.1m439.7m470.5m487.7m497.2m
show all
Annual
USDFY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016

Net Income

509.2m328.0m530.1m689.8m294.5m135.4m531.4m

Depreciation and Amortization

104.9m115.1m136.3m146.4m174.1m193.1m213.4m

Inventories

(32.9m)(14.6m)(25.0m)(35.9m)(53.9m)(33.1m)(83.7m)

Cash From Operating Activities

637.8m721.5m661.2m1.1b660.0m798.1m546.6m
Quarterly
USDQ1, 2010Q2, 2010Q3, 2010Q1, 2011Q2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Net Income

121.2m245.5m373.0m131.9m84.1m214.2m138.7m272.6m401.9m90.7m(70.9m)22.3m148.4m29.0m160.3m139.8m85.1m(900.0k)116.2m275.4m371.8m178.1m317.8m411.9m

Depreciation and Amortization

24.3m49.5m77.3m28.2m56.8m84.4m33.4m67.8m101.4m35.4m70.6m106.0m42.5m85.0m127.7m46.1m94.1m143.0m53.0m107.5m160.7m51.0m103.3m155.5m

Inventories

3.6m(12.6m)(38.3m)(14.4m)(16.4m)(19.8m)(6.8m)(27.1m)(34.0m)(8.3m)(23.1m)(34.4m)(13.7m)(27.9m)(45.9m)(20.6m)(33.0m)(38.5m)(21.3m)(53.8m)(78.7m)(19.9m)(44.0m)(71.2m)

Cash From Operating Activities

181.4m295.3m463.7m177.7m309.4m549.4m165.7m233.7m427.2m141.0m215.7m417.0m114.3m284.0m538.4m114.0m507.4m681.3m67.2m156.1m344.2m140.6m317.0m526.8m
show all
USDQ1, 2010

Financial Leverage

1.3 x
Show all financial metrics

C. R. Bard Cybersecurity Score

Cybersecurity ratingPremium dataset

B

82/100

Learn more about our premium products
SecurityScorecard logo

C. R. Bard Online and Social Media Presence

C. R. Bard's Trends

Embed Graph

C. R. Bard Company Culture

  • Overall Culture

    A+

    79/100

  • CEO Rating

    B+

    75/100

  • Compensation

    B

    71/100

Learn more on Comparably

C. R. Bard News and Updates

August 04, 2021

C.R. Bard Implant Called 'Ticking Time Bomb' At Trial Open

Counsel for a retired carpenter implanted with C.R. Bard's clot-stopping vein filter told a federal jury as the trial opened Wednesday that the filter broke, sending metal shards into his lungs and creating "a ticking time bomb in his body," while the company's counsel countered that ...
January 08, 2019

Strategic Focus Report on Hemostatic Agents Market 2019-2025: Baxter Ethicon US, LLC, Pfizer Inc., and C. R. Bard Inc.

An antihemorrhagic agent is a substance that promotes hemostasis (stops bleeding). It may also be known as a hemostatic (also spelled hæmostatic) agent. Posted via Industry Today. Follow us on Twitter @IndustryToday
December 18, 2018

Global Venous Stents Market Report 2017-2018 & 2025 with Performance of Key Players - Boston Scientific & C. R. Bard

DUBLIN, Dec. 18, 2018 /PRNewswire/ -- The "Venous Stents Market to 2025 - Global Analysis and Forecasts by Technology; Application; Disease; and Geography" report has been added to ResearchAndMarkets.com's offering. In the report the venous stents market, the market is expected to reach...
December 07, 2018

Pregnancy Detection Kit 2018 Global Market Key Players - Princeton BioMeditech, Walgreens, INSIGHT Pharmaceuticals, SPD, C. R. Bard, Confirm Biosciences, KIP Diagnostics.....

Pregnancy Detection Kit – Global Market Growth, Opportunities, Analysis of Top Key Players and Forecast to 2023 Posted via Industry Today. Follow us on Twitter @IndustryToday
September 25, 2018

Pancreatic Stents Market 2018: Global Analysis by Key Players – Boston Scientific, C. R. Bard, Becton, Cantel Medical, Olympus

Wiseguyreports.Com Publish New Market Research Report On -“Pancreatic Stents Market - Global Industry Analysis, Size, Share, Trends, Growth and Forecast 2018 - 2023” Posted via Industry Today. Follow us on Twitter @IndustryToday
September 11, 2018

Tissue Engineering Market Comprehensive Study by Leading Key Players: Allergan, Integra Lifesciences, C. R. Bard

Stay up-to-date with Tissue Engineering Market offered by HTF MI. Check how key trends and emerging drivers are shaping this industry growth. Posted via Industry Today. Follow us on Twitter @IndustryToday
Show more

C. R. Bard Blogs

June 22, 2022

BD Announces Voluntary Recall on Intraosseous Products

June 13, 2022

BD Collaborates with Mayo Clinic Platform, Leveraging Real-World Clinical Data to Improve Post-Market Device Surveillance, Drive Innovation for Patient Care

June 08, 2022

CerTest Biotec and BD Announce Collaboration on Molecular Diagnostic Test for Monkeypox

June 03, 2022

BD Unveils World's First Spectral Cell Sorter with High-Speed Imaging Technology that Sorts Cells Based on Visual Characteristics

May 18, 2022

BD and Mitsubishi Gas Chemical have signed a letter of intent (LOI) to discuss a partnership agreement to explore new ways to advance biologic drug delivery

Companies to work together with the aim of optimizing advanced technologies for use in prefillable syringes
April 29, 2022

BD to Present at the BofA Securities 2022 Healthcare Conference

Show more

 C. R. Bard Frequently Asked Questions

  • When was C. R. Bard founded?

    C. R. Bard was founded in 1907.

  • How many employees does C. R. Bard have?

    C. R. Bard has 3,008 employees.

  • What is C. R. Bard revenue?

    Latest C. R. Bard annual revenue is $3.7 b.

  • What is C. R. Bard revenue per employee?

    Latest C. R. Bard revenue per employee is $1.2 m.

  • Who are C. R. Bard competitors?

    Competitors of C. R. Bard include Dentsply Sirona, Cortron and BELKIN Vision.

  • Where are C. R. Bard offices?

    C. R. Bard has offices in Franklin Lakes, Chelmsford, Covington, Salt Lake City and in 31 other locations.

  • How many offices does C. R. Bard have?

    C. R. Bard has 42 offices.